Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016074 · ClinicalTrials.gov registry record · Phase 2
Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury
A Phase 2 study of Kidney Injury, Acute, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07016074 is a Phase 2 study of Kidney Injury, Acute that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07016074, a Phase 2 study of Kidney Injury, Acute, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study is designed to test the logistics and recruitment of a trial testing the benefit of sodium nitrate in the prevention of contrast-associated kidney injury in a group of patients at high-risk.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sodium Nitrate
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07016074
The ClinicalTrials.gov registry entry for NCT07016074 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Injury, Acute appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07016074 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07016074 about?
NCT07016074 is a clinical study titled "Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury". This pilot study is designed to test the logistics and recruitment of a trial testing the benefit of sodium nitrate in the prevention of contrast-associated kidney injury in a group of patients at high-risk.
What is the current status of trial NCT07016074?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-06-30. Estimated completion is 2026-07.
What conditions does trial NCT07016074 study?
This clinical trial studies the following conditions: Kidney Injury, Acute.
What interventions are being tested in trial NCT07016074?
The interventions under investigation include: Placebo (DRUG), Sodium Nitrate (DRUG).
Who is sponsoring clinical trial NCT07016074?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07016074 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Injury, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.